Pharmacokinetic evaluation of lamivudine and zidovudine tablets in human plasma;Avaliação farmacocinética de comprimidos contendo lamivudina e zidovudina em plasma humano

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 40, Issue 1, 2004, Pages 59-66

  Do Nascimento, João Eudes ^a,c   Magalhães, Nereide Stela Santos ^b   Ribeiro, Roseane Maria ^b   Pontes, Adriana ^b   Alves, Antônio José ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b Depto de Biol Cel e Ultraestrut   (Brazil)

^c University Cidade   (Brazil)

Author keywords

Lamivudine; Pharmacokinetic; Zidovudine

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CALCULATION; DOSE TIME EFFECT RELATION; DRUG FORMULATION; HUMAN; PLASMA; TABLET;

EID: 4043178418     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-93322004000100010     Document Type: Article

References (24)

1. BARRY, M.; HOWE, J. L.; ORMESHER, S.; BACK, D. J.; BRECKENRIDGE, A. M.; BERGIN, C.; MULCAHY, F.; BEECHING, N.; NYE, F. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br. J. Clin. Pharm., v.37, p.421-26, 1994.
2. BLANEY, S. M.; DANIEL, M. J.; HARKER, A. J.; GODWIN, K.; BALIS, F. M. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebroespinhal fluid of nonhuman primates. Antimicrob. Agents Chemother., v.39, n.12, p.2779-2782, 1995.
3. BLUM, M. R.; LIAO, S. H.; GOOD, S. S.; DE MIRANDA, P. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med., v. 85, n.2A, p.189-94, Aug 1988.
4. CARPENTER, C. C.; FISCHL, M. A.; HAMMER, S. M.; HIRSCH, M. S.; JACOBSEN, D. M.; KATZENSTEIN, D. A.; MONTANER, J. S.; RICHMAN, D. D.; SAAG, M. S.; SCHOOLEY, R. T.; THOMPSON, M. A.; VELLA, S.; YENI, P. G.; VOLBERDING. P. A. Antiretroviral therapy for Infection in 1996. J. Am. Med. Assoc. JAMA, v.276, n.2, p.146-54,1996.
5. FÖLDES, O.; UHEROVA P.; MAYER, V. Plasma levels of the anti-HIV drug 3′-azido-2′,3′-dideoxythymidine (AZT): determination by RIA and HPLC. Acta Virol., v. 37, n.2-3, p.156-64, 1993.
6. GOOD, S. S.; DURACK, D. T.; DE MIRANDA, P. Biotransformation in various species and in humans of 3′-azido-3′-deoxy-thymidine, a potential agent for the treatment of AIDS. Fed. Proc. v.45, n.3, p.444, 1986.
7. HEALD, A. E.; HSYU, P. H.; YUEN, G. J.; ROBINSON, P.; MYDLOW, P.; BARTLETT, J. A. Pharmacokinetics of human immunodeficiency virus-infected patients with renal disfunction. Antimicrob. Agents Chemother., v.40, p.1514-1519. 1996.
8. HEDAYA, M. A.; SAWCHUK, R. J. A sensitive liquid-chromatographic method for determination of 3′-azido-3′deoxythymidine (AZT) in plasma and urine. Clin. Chem., v.34, n. 8, p.1565-68, 1988.
9. HENRY, K.; CHINNOCK, B. J.; QUINN, R. P.; FLETCHER, C. V.; DE MIRANDA, P.; BALFOUR Jr., H. H.. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. J. Am. Med. Assoc. JAMA, v. 259, p.3023-26,1988.
10. JOHNSON, M. A.; MOORE, K. H.; YUEN, G. J.; BYE, A.; PAKES, G. E. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet., v.36, n.1, p.41-66, 1999.
11. KLECKER Jr., R. W; COLLINS, J. M.; YARCHOAN, R.; THOMAS, R.; JENKINS, J. F.; BRODER, S.; MYERS, C. E. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin. Pharmacol. Ther., v.41, n.4, p.407-12, 1987.
12. LANGTRY, H. D.; CAMPOLI-RICHARDS, D. M. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic effcacy. Drugs, v.37. p.408-50, 1989.
13. LARDER, B. A.; KEMP, S. D.; HARRIGAM, P. R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science, v.269, p.696-99, 1995.
14. LEWIS, L. L.; VEZON, D.; CHURCH, J. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis., v.174, p.16-25, 1996.
15. MOODLEY, J.; MOODLEY, D.; PILLAY, K.; COOVADIA, H.; SABA, J.; VAN LEEUWEN, R.; GOODWIN, C.; HARRIGAN, P. R.; MOORE, K. H.; STONE, C.; PLUMB, R.; JOHNSON, M. A. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J. Infect. Dis., v.178, n.5, p. 1327-33,1998.
16. MOORE, K. H.; YUEN, G. F.; RAASCH, R. H.; ERON, J. J.; MARTIN, D.; MYDLOW, P. K.; HUSSEY, E. K. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin. Pharmacol. Therap., v.59, n.5, p.550-558, 1996.
17. MOORE, K. H.; SHAW, S.; LAURENT, A. L.; LLOYD, P.; DUNCAN, B.; MORRIS, D. M.; O'MARA, M. J.; PAKES, G. E. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J. Clin. Pharmacol., v.39,n. 6, p.593-605, 1999.
18. PERRY, C. M.; FAULDES, D. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HW infection. Drugs, v. 53, p.657-680, 1997.
19. ROBBINS, B. L.; TRAN, T. T.; PINKERTON, F. H. Jr.; AKEB, F.; GUEDJ, R.; GRASSI, J.; LANCASTER, D.; FRIDLAND, A. Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother., v. 42, n.10, p.2656-60, 1998.
20. SANTOS-MAGALHAES, N. S.; PONTES, A.; CAVALCANTE, R. M.; COSTA, R. M.; RANGEL, F. A.; GUIMARAES, M. I.; DE CARVALHO J. N.; DE SOUZA, S. D.; DE OLIVEIRA, H. M.; ESTEVES, I. L.; RAMALHO, M. S.; VIEIRA, S. L.; ALVES, A. J. Bioequivalence of two lamivudine tablets. Arneimittel-Forschung. Drug Res., v.51, n.04, p.1-10, 2001.
21. SLUSHER, J. T.; KUWAHARA, S. K.; HAMZEH, F. M.; LEWIS, L. D.; KORNHAUSER, D. M.; LIETMAN, P. S. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography- radioimmunoassay procedure. Antimicrob. Agents Chemother., v.36, n.11, p.2473-7, 1992.
22. VAN LEEUWEN, R.; KATLAMA, C.; KITCHEN, V. Evaluation of safety efficacy of 3TC (Lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis., v.171, p.1166-71, 1995.
23. VAN LEEUWEN, R.; LANGE, J. M.; HUSSEY, E. K.; DONN, K. H.; HALL, S. T.; HARKER, A. J.; JONKER, P.; DANNER, S. A. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HTV infection: a phase I study. AIDS., v.6, n.12, p.1471-5, 1992.
24. WANG, L. H.; CHITTICK, G. E.; McDOWELL, J. A. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob. Agents Chemother., v.43, n.7, p.1708-15, 1999.